These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors]. Broncel M; Balcerak M; Chojnowska-Jezierska J Pol Merkur Lekarski; 2007 Jan; 22(127):62-5. PubMed ID: 17477094 [TBL] [Abstract][Full Text] [Related]
3. Simvastatin + ezetimibe: a combination with no proven advantages. Prescrire Int; 2007 Apr; 16(88):67. PubMed ID: 17460829 [No Abstract] [Full Text] [Related]
4. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099 [TBL] [Abstract][Full Text] [Related]
5. Ezetimibe/simvastatin (INEGY) in the treatment of hyperlipidaemia. Kastelein JJ; Sankatsing RR Int J Clin Pract; 2005 Dec; 59(12):1464-71. PubMed ID: 16351680 [TBL] [Abstract][Full Text] [Related]
6. [Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?]. Sudhop T; von Bergmann K MMW Fortschr Med; 2003 May; 145(21):19. PubMed ID: 12845862 [No Abstract] [Full Text] [Related]
7. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis (the SEAS trial). Farmer JA Curr Atheroscler Rep; 2009 Mar; 11(2):82-3. PubMed ID: 19228479 [No Abstract] [Full Text] [Related]
8. Lipid-lowering study raises issues of therapy's value. Thompson CA Am J Health Syst Pharm; 2008 Apr; 65(7):594-5. PubMed ID: 18359962 [No Abstract] [Full Text] [Related]
9. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Hou R; Goldberg AC Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials. Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168 [TBL] [Abstract][Full Text] [Related]
11. After the failure of ENHANCEd cholesterol lowering in familial hypercholesterolemia, SEAS of problems with ezetimibe. Mascitelli L; Ravnskov U; Pezzetta F; Goldstein MR Angiology; 2009; 60(1):127-8; author reply 129-30. PubMed ID: 19049996 [No Abstract] [Full Text] [Related]
12. Clinical inquiries. What are effective medication combinations for dyslipidemia? Saseen J; Tweed E; Crawford P J Fam Pract; 2006 Jan; 55(1):70-2. PubMed ID: 16388773 [No Abstract] [Full Text] [Related]
14. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326 [TBL] [Abstract][Full Text] [Related]
15. Setting a new standard in achieving superior efficacy: ezetimibe + simvastatin. Farnier M Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():27-8. PubMed ID: 18001317 [TBL] [Abstract][Full Text] [Related]
19. Rx for uncertainty. Does a popular cholesterol-lowering drug do what it's supposed to do? Law BM Diabetes Forecast; 2008 Mar; 61(3):19. PubMed ID: 18446972 [No Abstract] [Full Text] [Related]
20. [Type 2 diabetics are high risk patients. Concerning LDL-cholesterol to approach effectively to two sources]. MMW Fortschr Med; 2005 Nov; 147(44):52-3. PubMed ID: 16302495 [No Abstract] [Full Text] [Related] [Next] [New Search]